Marrita Murphy

Marrita Murphy serves as a Contract Specialist responsible for managing the full lifecycle of federal acquisitions, from requirement validation and market research through solicitation, award, and contract administration. She plays a critical role in ensuring compliance with the Federal Acquisition Regulation (FAR) and advancing the agency’s mission through transparent, competitive procurement processes. Her portfolio primarily encompasses complex procurements in pharmaceutical manufacturing, diagnostic sciences, and life sciences research, requiring deep technical understanding and precise contract language to address regulatory, quality, and supply chain considerations. She frequently handles both commercial and non-commercial contracts, including those requiring specialized certifications and performance-based service agreements. While specific contractor names are not available, Marrita Murphy engages with a diverse range of vendors, including small businesses, research institutions, and manufacturers with expertise in life sciences and laboratory services. Her contracting patterns reflect a balanced approach between open competition and targeted set-asides, fostering relationships with firms capable of delivering high-compliance, high-precision products and services. She maintains collaborative working relationships with industry stakeholders to ensure market readiness and foster innovation in regulated environments. Marrita demonstrates a strong commitment to socioeconomic contracting, with half of her acquisitions structured as Total Small Business Set-Asides under FAR 19.5, aligning with federal goals to expand opportunities for small businesses. The remaining half are awarded without set-asides, reflecting a strategic balance between competition and small business inclusion. Her approach supports broad participation across small business categories without preference for specific socioeconomic designations, emphasizing capability and compliance over classification. Her primary procurement focus lies in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325413 (In-Vitro Diagnostic Substance Manufacturing), each accounting for one-third of her portfolio, alongside significant activity in NAICS 541712 (Life Sciences R&D) and 561110 (Office Administrative Services). She specializes in procuring clinical-grade pharmaceuticals, diagnostic reagents, laboratory support services, and scientific research solutions, demonstrating deep familiarity with FDA-regulated environments and Good Manufacturing Practices (GMP).